Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP623519.RAbyZ57HP0iWa-9ocH4Me9EjDJ8D0fnmr0MsH1FByVAmo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP623519.RAbyZ57HP0iWa-9ocH4Me9EjDJ8D0fnmr0MsH1FByVAmo130_assertion type Assertion NP623519.RAbyZ57HP0iWa-9ocH4Me9EjDJ8D0fnmr0MsH1FByVAmo130_head.
- NP623519.RAbyZ57HP0iWa-9ocH4Me9EjDJ8D0fnmr0MsH1FByVAmo130_assertion description "[Activating mutations in the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathway are present in the majority of breast cancers and therefore are a major focus of drug development and clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP623519.RAbyZ57HP0iWa-9ocH4Me9EjDJ8D0fnmr0MsH1FByVAmo130_provenance.
- NP623519.RAbyZ57HP0iWa-9ocH4Me9EjDJ8D0fnmr0MsH1FByVAmo130_assertion evidence source_evidence_literature NP623519.RAbyZ57HP0iWa-9ocH4Me9EjDJ8D0fnmr0MsH1FByVAmo130_provenance.
- NP623519.RAbyZ57HP0iWa-9ocH4Me9EjDJ8D0fnmr0MsH1FByVAmo130_assertion SIO_000772 23888070 NP623519.RAbyZ57HP0iWa-9ocH4Me9EjDJ8D0fnmr0MsH1FByVAmo130_provenance.
- NP623519.RAbyZ57HP0iWa-9ocH4Me9EjDJ8D0fnmr0MsH1FByVAmo130_assertion wasDerivedFrom befree-20150227 NP623519.RAbyZ57HP0iWa-9ocH4Me9EjDJ8D0fnmr0MsH1FByVAmo130_provenance.
- NP623519.RAbyZ57HP0iWa-9ocH4Me9EjDJ8D0fnmr0MsH1FByVAmo130_assertion wasGeneratedBy ECO_0000203 NP623519.RAbyZ57HP0iWa-9ocH4Me9EjDJ8D0fnmr0MsH1FByVAmo130_provenance.